HDAC inhibition synergistically enhances alkylator-induced DNA damage responses and apoptosis in multiple myeloma cells.
Histone deacetylase (HDAC) inhibitors induce chromatin destabilization. We sought to determine whether HDAC inhibition may amplify alkylator-induced mitotic cell death in multiple myeloma (MM) cells. The combination of SNDX-275, a class I HDAC inhibitor, with melphalan, showed a powerful synergism on growth inhibition with the combination index ranged from 0.27 to 0.75 in MM1.S and RPMI8226 cells. Their combinations as compared with either agent alone promoted much more caspase-dependent apoptosis. Flow cytometry analysis showed that SNDX-275 had minimal effects on cell cycle progression of MM1.S cells, but clearly increased the percentage of S phase in RPMI8226 cells associated with an upregulation in p21(waf1) and a reduction in cyclin D1 and E2F1. Melphalan alone significantly arrested both MM1.S and RPMI8226 cells at S phase and enhanced expression of p53 and p21(waf1). Furthermore, studies on DNA damage response revealed that phospho-histone H2A.X (gammaH2A.X), a hall marker of DNA double strand break, along with phosphorylated CHK1 (P-CHK1) and CHK2 (P-CHK2) was dramatically induced by SNDX-275 or melphalan. The increase in gammaH2A.X and P-CHK1 was considerably higher on combination than either agent alone. These molecular changes correlated well with the significant increase in mitotic catastrophe. Our data indicate that SNDX-275 synergistically enhances melphalan-induced apoptosis in MM cells via intensification of DNA damage, suggesting that SNDX-275 in combination with melphalan may be a novel therapeutic strategy for MM.
Lee
Choon-Kee
CK
Department of Medicine, University of Colorado Denver School of Medicine, Aurora, 80045, USA. choon-kee.lee@ucdenver.edu
Wang
Shuiliang
S
Huang
Xiaoping
X
Ryder
John
J
Liu
Bolin
B
D017209:Apoptosis / Q000187:drug effects*; D002453:Cell Cycle / Q000187:drug effects; D002455:Cell Division / Q000187:drug effects; D045744:Cell Line, Tumor / Q000187:drug effects; D004249:DNA Damage / Q000187:drug effects*; D056572:Histone Deacetylase Inhibitors / Q000494:pharmacology*; D006801:Humans; D008558:Melphalan / Q000627:therapeutic use*; D008938:Mitosis / Q000187:drug effects; D009101:Multiple Myeloma / Q000188:drug therapy / Q000235:genetics* / Q000473:pathology
D056572:Histone Deacetylase Inhibitors; D008558:Melphalan
Cancer Sci. 2008 Feb;99(2):376-84
18201278
Blood. 2003 May 15;101(10):4055-62
12531799
Clin Cancer Res. 2004 Sep 15;10(18 Pt 1):6066-71
15447991
Cancer Res. 2002 Nov 1;62(21):6108-15
12414635
Adv Enzyme Regul. 1984;22:27-55
6382953
Cancer Res. 2003 Nov 1;63(21):7291-300
14612526
Best Pract Res Clin Haematol. 2007 Dec;20(4):797-816
18070720
Curr Biol. 2010 Mar 9;20(5):387-96
20188555
Cancer Res. 2006 Dec 1;66(23):11298-304
17145876
Clin Exp Metastasis. 2008;25(2):183-9
18058245
Oncogene. 2007 Aug 13;26(37):5541-52
17694093
J Biol Chem. 1977 Sep 25;252(18):6438-42
893418
Br J Haematol. 2001 Dec;115(3):522-40
11736932
Cancer Res. 2006 Jun 1;66(11):5781-9
16740717
Int J Cancer. 2004 Nov 1;112(2):171-8
15352027
Nat Rev Cancer. 2006 Jan;6(1):38-51
16397526
J Cell Biochem. 2009 Jul 1;107(4):600-8
19459166
Cell. 2007 Feb 23;128(4):693-705
17320507
Neoplasia. 2005 Jul;7(7):646-57
16026644
Leukemia. 2009 Jan;23(1):10-24
18843284
Nat Rev Cancer. 2007 Aug;7(8):585-98
17646864
Nat Rev Drug Discov. 2006 Sep;5(9):769-84
16955068
Cancer Res. 2009 Jun 15;69(12):5015-22
19491273
Curr Opin Genet Dev. 1999 Apr;9(2):171-4
10322142
Haematologica. 2006 Feb;91(2):248-51
16461312
J Natl Cancer Inst. 2006 Aug 16;98(16):E2
16912255
Cancer Res. 2008 Aug 15;68(16):6718-26
18701496
J Clin Oncol. 2005 Sep 10;23(26):6345-50
16155018
J Cell Biochem. 2005 Apr 15;94(6):1088-102
15723344
Arch Physiol Biochem. 2009 May;115(2):49-57
19234898
Blood. 2006 Nov 15;108(10):3441-9
16728695
Nature. 2003 Jan 30;421(6922):499-506
12556884
N Engl J Med. 2004 Oct 28;351(18):1860-73
15509819
Proc Natl Acad Sci U S A. 2004 Feb 3;101(5):1241-6
14734806
Cancer Res. 2009 Nov 1;69(21):8403-11
19826038
Clin Cancer Res. 2004 Jun 1;10(11):3839-52
15173093
Blood. 2003 Oct 1;102(7):2615-22
12816865
Cancer Res. 2003 Jul 1;63(13):3637-45
12839953
Oncogene. 2007 Aug 13;26(37):5310-8
17694074
Blood. 2009 May 7;113(19):4614-26
19228610
Mol Cancer Res. 2007 Oct;5(10):981-9
17951399
Clin Cancer Res. 2009 Mar 15;15(6):1998-2009
19276263
J Cell Biol. 2007 Sep 24;178(7):1101-8
17893239
Proc Natl Acad Sci U S A. 2004 Jan 13;101(2):540-5
14695887
Curr Opin Genet Dev. 2005 Oct;15(5):490-5
16098738
Leukemia. 2004 Jul;18(7):1207-14
15116122
Cancer Cell. 2007 Sep;12(3):252-65
17785206
Exp Cell Res. 2007 Jul 1;313(11):2378-88
17462628
Leukemia. 2005 Oct;19(10):1729-38
16094421
Proc Natl Acad Sci U S A. 1999 Apr 13;96(8):4592-7
10200307
Oncogene. 2005 Jul 7;24(29):4609-23
15897906
Exp Hematol. 2003 Apr;31(4):271-82
12691914
Blood. 2007 Apr 1;109(7):2781-90
17179232